The Molecular Therapeufics of Cancer Program (MTCP) is a """"""""translational research"""""""" effort interfacing basic scientists with clinicians specializing in cancer diagnosis and treatment. The program has deep strengths in lung cancer research and has used this experience to catalyze addifional research that links disease oriented teams and basic researchers. The MTCP also provides a major series of bridges through its interactions other Cancer Center Programs. The goals of the MTCP are to understand the molecular events (genetic and epigenefic) leading to cancer, as well as understanding the role of inter-individual genefic variation in developing and treating cancer, and use this informafion to provide a rafionale basis for developing novel diagnostic, prevention, and therapeutic strategies. Specifically the MTCP seeks to: ? Understand the molecular pathogenesis of cancers with a focus on human tissues and model systems with a particular emphasis on lung cancer. This includes both descripfion of the abnormalifies and demonstrating their funcfional relevance as biologic, therapeufic and diagnostic targets. ? Develop new cancer imaging and nanotechnology tools to deliver novel imaging agents and therapeufics to highlight these targets in vivo in preclinical model and later in the clinic. ? Develop molecular therapeutics including those involving or combined with radiafion targeted at the abnormalities found in studies of the molecular pathogenesis as well as the identificafion and use of specific cell surface markers characterisfic of certain cancers as therapeufic targets. ? Develop tumor molecular biomarkers that allow predicfion of clinical behavior and response to specific treatments of individual patients so that treatment can be """"""""personalized."""""""" ? Use advances in the other Cancer Center Programs (Chemistry and Cancer, Cancer Cell Networks, and Development and Cancer) to inform each of these prior themes in a way that is unique to the Simmons Cancer Center and that will provide synergy of research efforts and facilitate translafion to the clinic at UTSW.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-03
Application #
8380771
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$21,067
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851
Rutkowski, Joseph M; Pastor, Johanne; Sun, Kai et al. (2017) Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91:324-337
Singh, Jaspal; Rustagi, Vineeta; Zhang, Shanrong et al. (2017) On-bead combinatorial synthesis and imaging of europium(III)-based paraCEST agents aids in identification of chemical features that enhance CEST sensitivity. Magn Reson Chem 55:747-753
Singh, Dinesh K; Kollipara, Rahul K; Vemireddy, Vamsidara et al. (2017) Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. Cell Rep 18:961-976
Gu, Yi-Feng; Cohn, Shannon; Christie, Alana et al. (2017) Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov 7:900-917
Lee, Ming Y; Sumpter Jr, Rhea; Zou, Zhongju et al. (2017) Peroxisomal protein PEX13 functions in selective autophagy. EMBO Rep 18:48-60
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Howard, James J; Sturge, Carolyn R; Moustafa, Dina A et al. (2017) Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Antimicrob Agents Chemother 61:
Skinner, Celette Sugg; Ahn, Chul; Halm, Ethan A et al. (2017) Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. Prev Med 102:20-23
Garcia, Sandra; Bisen, Ajit; Yan, Jingsheng et al. (2017) Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12:1489-1495

Showing the most recent 10 out of 441 publications